Aquablation Therapy Market Report: Trends, Forecast and Competitive Analysis to 2035

Aquablation Therapy Market Trends and Forecast

The future of the global aquablation therapy market looks promising with opportunities in the benign prostatic hyperplasia and prostate tissue debulking markets. The global aquablation therapy market is expected to reach an estimated $6.4 billion by 2035 with a CAGR of 11.6% from 2026 to 2035. The major drivers for this market are the increasing number of prostate surgery procedures, the rising demand for minimally invasive treatments, and the growing awareness of advanced urological technologies.

• Lucintel forecasts that, within the type category, single-use handpiece is expected to witness the highest growth over the forecast period.
• Within the application category, benign prostatic hyperplasia is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Aquablation Therapy Market

The aquablation therapy market is experiencing rapid growth driven by technological advancements, increasing prevalence of prostate conditions, and a shift towards minimally invasive procedures. As healthcare providers seek more effective and patient-friendly treatment options, the market is witnessing significant innovations and expanding adoption across various regions. These developments are not only improving clinical outcomes but also transforming the landscape of urological care. The following key trends highlight the major forces shaping this evolving market, reflecting its trajectory towards more personalized, efficient, and accessible therapies.

• Technological Innovations: Advancements in robotic and imaging technologies are enhancing the precision and safety of Aquablation procedures. Newer systems incorporate real-time imaging and automation, reducing procedure times and improving outcomes. These innovations enable surgeons to target prostate tissue more accurately, minimizing side effects and recovery time. As technology continues to evolve, the market is likely to see increased adoption of more sophisticated, user-friendly devices that cater to a broader patient demographic.
• Growing Prevalence of Prostate Conditions: The rising incidence of benign prostatic hyperplasia (BPH) and prostate cancer globally is fueling demand for effective treatments like Aquablation. Aging populations and lifestyle factors contribute to higher case numbers, prompting healthcare systems to seek minimally invasive solutions that offer quick recovery and fewer complications. This trend is expanding the patient base and encouraging healthcare providers to incorporate Aquablation as a standard treatment option, thereby boosting market growth.
• Increasing Adoption of Minimally Invasive Procedures: There is a clear shift from traditional surgical methods to minimally invasive therapies in urology. Aquablation offers benefits such as reduced bleeding, shorter hospital stays, and quicker return to daily activities. This trend aligns with patient preferences for less invasive options and healthcare providers’ goals to improve efficiency and reduce costs. As awareness grows, more clinics and hospitals are adopting Aquablation, further expanding its market reach and acceptance.
• Rising Investment and R&D Activities: Significant investments by medical device companies and research institutions are accelerating the development of next-generation Aquablation systems. Focus areas include enhancing device precision, reducing costs, and expanding indications. These R&D efforts are leading to innovative solutions that improve clinical outcomes and patient safety. Increased funding and collaboration are expected to drive market expansion, facilitate regulatory approvals, and foster global adoption of advanced Aquablation technologies.
• Regulatory Approvals and Reimbursement Policies: The approval of Aquablation devices by regulatory authorities and favorable reimbursement policies are critical for market growth. Clear guidelines and coverage options encourage healthcare providers to adopt this therapy more widely. Governments and insurers are recognizing the benefits of minimally invasive treatments, which can reduce long-term healthcare costs. As regulatory landscapes become more supportive, the market is poised for accelerated growth, with increased accessibility and adoption across diverse healthcare settings.

In summary, these trends are collectively reshaping the aquablation therapy market by fostering technological progress, expanding patient access, and promoting more efficient healthcare delivery. The market is moving towards more innovative, patient-centric solutions that are set to redefine urological treatment paradigms in the coming years.

Recent Developments in the Aquablation Therapy Market

The aquablation therapy market is experiencing rapid growth driven by technological advancements and increasing demand for minimally invasive treatments. As healthcare providers seek effective solutions for prostate conditions, innovations in Aquablation are expanding its applications and accessibility. This evolving landscape presents significant opportunities for market expansion, improved patient outcomes, and competitive differentiation. Stakeholders are investing heavily in research, development, and strategic partnerships to capitalize on these emerging trends and meet the rising global demand for advanced urological therapies.

• Growing Adoption of Minimally Invasive Procedures: The increasing preference for minimally invasive treatments is boosting Aquablations popularity. Patients favor procedures with reduced recovery times, fewer complications, and less discomfort. Healthcare providers are adopting Aquablation as a preferred option for prostate treatment, leading to higher market penetration. This trend is supported by technological improvements and positive clinical outcomes, which are driving demand across hospitals and clinics worldwide. The market is expected to expand as awareness and acceptance grow.
• Technological Innovations Enhancing Precision: Recent advancements in robotic systems and imaging technologies have significantly improved the precision of Aquablation therapy. These innovations enable more accurate targeting of prostate tissue, minimizing damage to surrounding areas. Enhanced control and real-time feedback improve safety and efficacy, encouraging wider adoption. As technology continues to evolve, the procedure becomes more accessible and reliable, attracting new users and expanding the market. This progress is crucial for establishing Aquablation as a standard treatment option.
• Increasing Prevalence of Prostate Conditions: The rising incidence of prostate-related disorders, such as benign prostatic hyperplasia (BPH), is fueling demand for effective treatments like Aquablation. Aging populations and lifestyle factors contribute to higher case numbers globally. This growing patient base creates a substantial market opportunity for providers offering innovative solutions. The ability of Aquablation to deliver consistent, minimally invasive results makes it an attractive choice for managing these conditions, further driving market growth and encouraging investment in related technologies.
• Expanding Geographic Reach and Market Penetration: Efforts to increase awareness and improve healthcare infrastructure are expanding Aquablations reach into emerging markets. Strategic collaborations and training programs are facilitating adoption in regions with previously limited access to advanced urological treatments. This geographic expansion is opening new revenue streams and diversifying the market landscape. As more healthcare systems incorporate Aquablation into their treatment protocols, the global market is expected to see significant growth, especially in Asia-Pacific and Latin America.
• Increasing Investment and Strategic Partnerships: The market is witnessing heightened investment from medical device companies and healthcare providers aiming to develop next-generation Aquablation systems. Strategic partnerships are fostering innovation, clinical research, and commercialization efforts. Funding for R&D is accelerating the development of more efficient, user-friendly devices and expanding clinical evidence supporting the therapy. These collaborations are crucial for market growth, enabling faster adoption, regulatory approvals, and broader availability, ultimately strengthening the competitive landscape.

The overall impact of these developments is a robust expansion of the aquablation therapy market, driven by technological progress, increased demand, and strategic efforts to broaden access. These factors are collectively enhancing treatment options, improving patient outcomes, and fostering innovation, positioning Aquablation as a leading minimally invasive solution for prostate conditions worldwide.

Strategic Growth Opportunities in the Aquablation Therapy Market

Aquablation therapy is emerging as a minimally invasive treatment option for benign prostatic hyperplasia (BPH). As technological advancements and increasing patient awareness drive demand, the market is poised for significant growth. Key applications across healthcare settings, expanding patient populations, and innovations in device design are creating new opportunities. Strategic investments and collaborations will be essential for market players to capitalize on these trends and expand their global footprint.

• Expansion into Emerging Markets: Aquablation therapy presents a significant growth opportunity in developing regions where BPH prevalence is rising. Increasing healthcare infrastructure, rising awareness, and the adoption of minimally invasive procedures are fueling demand. Local manufacturers and global players can benefit from tailored marketing strategies, training programs, and affordable device options to penetrate these markets effectively. This expansion can lead to increased adoption rates and revenue growth for industry stakeholders.
• Integration with Robotic Surgical Systems: The integration of aquablation technology with robotic surgical platforms offers enhanced precision and control during procedures. This synergy can improve patient outcomes, reduce operative times, and minimize complications. As robotic systems become more prevalent in hospitals worldwide, developing compatible aquablation devices and training surgeons will be crucial. This integration represents a strategic avenue for innovation, differentiation, and capturing a larger share of the minimally invasive urology market.
• Development of Portable and User-Friendly Devices: The demand for portable, easy-to-use aquablation systems is increasing, especially in outpatient and ambulatory surgical settings. Compact devices with simplified interfaces can facilitate quicker procedures, reduce the need for extensive training, and expand access to a broader patient base. Manufacturers investing in ergonomic design, wireless connectivity, and streamlined workflows can capitalize on this trend, enabling more clinics to adopt aquablation therapy and driving overall market growth.
• Increasing Adoption in Refractory and Complex Cases: As clinical evidence supports the safety and efficacy of aquablation, its use in more complex and refractory BPH cases is expanding. This includes patients with larger prostates or those unresponsive to traditional therapies. Developing specialized protocols, training surgeons, and demonstrating long-term benefits will encourage clinicians to adopt aquablation for a wider patient demographic. This growth in application scope can significantly boost market size and revenue streams.
• Strategic Collaborations and Licensing Agreements: Collaborations between device manufacturers, healthcare providers, and research institutions can accelerate innovation and market penetration. Licensing agreements can facilitate technology transfer, reduce R&D costs, and expand distribution networks. Such strategic partnerships can also foster clinical research, validate new indications, and enhance product portfolios. These collaborations are vital for staying competitive, entering new markets, and driving sustained growth in the aquablation therapy market.

In conclusion, these growth opportunities are set to transform the aquablation therapy market by expanding its application scope, improving device technology, and increasing global accessibility. Embracing innovation, strategic partnerships, and market expansion will enable industry players to capitalize on the rising demand for minimally invasive urological treatments, ultimately improving patient outcomes and market competitiveness.

Aquablation Therapy Market Driver and Challenges

The aquablation therapy market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in minimally invasive procedures, increasing prevalence of benign prostatic hyperplasia (BPH), and supportive healthcare policies are key drivers. Conversely, challenges such as high procedural costs, regulatory hurdles, and limited awareness pose significant barriers. Understanding these drivers and challenges is essential for stakeholders aiming to capitalize on market opportunities and address potential risks. The interplay of innovation, market demand, and policy environment will ultimately determine the pace and sustainability of growth in this evolving sector.

The factors responsible for driving the aquablation therapy market include:

• Technological Innovation: The development of Aquablation technology offers a minimally invasive, precise, and effective treatment for BPH. This innovation reduces procedure time, minimizes complications, and enhances patient recovery, making it highly attractive to healthcare providers. As technology advances, improved devices and techniques are expected to expand indications and improve outcomes, fueling market growth. The continuous evolution of robotic and imaging integration further enhances procedural accuracy, attracting more clinicians and patients alike.
• Rising Prevalence of BPH: The increasing incidence of benign prostatic hyperplasia globally, especially among aging populations, significantly drives demand for effective treatments like Aquablation. As the demographic shifts toward older age groups, the need for minimally invasive, durable solutions grows. This trend is supported by epidemiological data indicating a rising burden of BPH-related symptoms, which compels healthcare systems to adopt innovative therapies to manage patient needs efficiently.
• Favorable Reimbursement Policies: Supportive reimbursement frameworks in key markets encourage adoption of Aquablation therapy. Insurance coverage and government healthcare policies that recognize the benefits of minimally invasive procedures reduce out-of-pocket expenses for patients and incentivize providers to adopt new technologies. This financial support accelerates market penetration and broadens access, especially in regions where cost barriers previously limited treatment options.
• Increasing Awareness and Acceptance: Growing awareness among healthcare professionals and patients about the benefits of Aquablation therapy is a crucial driver. Educational initiatives, clinical trial results, and positive patient outcomes contribute to increased acceptance. As more clinicians become trained and comfortable with the technology, and patients seek less invasive options, demand is expected to rise, further expanding the market.

The challenges in the aquablation therapy market are:

• High Procedural Costs: Despite its benefits, Aquablation therapy involves significant upfront costs related to advanced equipment, training, and procedure expenses. These costs can hinder adoption, especially in cost-sensitive healthcare settings or developing regions. Reimbursement limitations and budget constraints may slow market growth, requiring stakeholders to demonstrate long-term cost-effectiveness to justify initial investments.
• Regulatory and Approval Barriers: Navigating complex regulatory pathways remains a challenge for new medical devices and technologies. Lengthy approval processes, varying standards across regions, and the need for extensive clinical data can delay market entry and expansion. These hurdles increase time-to-market and costs for manufacturers, potentially limiting the availability of Aquablation therapy in certain markets.
• Limited Awareness and Training: Despite growing interest, a lack of widespread training and awareness among healthcare providers can impede adoption. Many clinicians may be unfamiliar with the procedure or hesitant to shift from traditional treatments. This knowledge gap necessitates comprehensive training programs and educational efforts, which require time and resources, potentially slowing market growth.

In summary, the aquablation therapy market is driven by technological advancements, increasing disease prevalence, supportive policies, and rising awareness. However, high costs, regulatory challenges, and limited provider training pose significant barriers. The overall impact of these factors will determine the market’s growth trajectory, with innovation and policy support likely to propel expansion, while cost and regulatory hurdles may temper it. Strategic efforts to address these challenges will be essential for sustained market development and improved patient outcomes.

List of Aquablation Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies aquablation therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the aquablation therapy companies profiled in this report include-

• PROCEPT BioRobotics
• Medtronic
• Olympus
• Boston Scientific
• Karl Storz

Aquablation Therapy Market by Segment

The study includes a forecast for the global aquablation therapy market by type, anesthesia type, site of care, application, and region.

Aquablation Therapy Market by Type [Value from 2019 to 2035]:

• Aquablation Consoles
• Single-use Handpieces
• Imaging & Planning Software

Aquablation Therapy Market by Anesthesia Type [Value from 2019 to 2035]:

• General Anesthesia
• Spinal Anesthesia
• Others

Aquablation Therapy Market by Site of Care [Value from 2019 to 2035]:

• Inpatient OR
• Ambulatory Surgery Center
• Others

Aquablation Therapy Market by Application [Value from 2019 to 2035]:

• Benign Prostatic Hyperplasia
• Prostate Tissue Debulking
• Others

Aquablation Therapy Market by Region [Value from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Aquablation Therapy Market

The aquablation therapy market has experienced significant growth driven by technological advancements, increasing prevalence of benign prostatic hyperplasia (BPH), and rising demand for minimally invasive procedures worldwide. Countries are adopting innovative solutions to improve patient outcomes and reduce healthcare costs. Regulatory approvals and expanding clinical evidence further support market expansion. As healthcare systems evolve, key players are investing in research and development to enhance device efficacy and safety. The following summaries highlight recent developments in the United States, China, Germany, India, and Japan, reflecting their unique contributions and market dynamics in this sector.

• United States: The US market has seen rapid adoption of Aquablation Therapy, driven by FDA approvals and extensive clinical trials demonstrating safety and efficacy. Leading healthcare providers are integrating this minimally invasive procedure into standard BPH treatment protocols. Technological innovations, such as improved imaging and robotic assistance, have enhanced precision. Reimbursement policies are favorable, encouraging wider adoption. Additionally, increasing awareness among urologists and patients has contributed to market growth. Ongoing research aims to compare Aquablation with traditional surgical options, further solidifying its position in the US healthcare landscape.
• China: China’s Aquablation Market is expanding due to rising BPH prevalence and increasing healthcare infrastructure investments. The government’s focus on minimally invasive treatments has facilitated faster adoption. Local manufacturers are developing cost-effective devices to cater to a large patient base. Clinical research collaborations with international institutions are enhancing product credibility. Growing awareness among urologists and patients about the benefits of Aquablation is boosting demand. Additionally, expanding insurance coverage and government initiatives to improve healthcare access are expected to accelerate market growth in the coming years.
• Germany: Germany’s market is characterized by high healthcare standards and a strong emphasis on innovative medical technologies. The adoption of Aquablation Therapy is supported by robust clinical evidence and approval from European regulatory bodies. Leading hospitals and urology centers are incorporating the procedure into their treatment options. Germany’s focus on minimally invasive solutions aligns with its healthcare policies aimed at reducing hospital stays and improving patient recovery times. Ongoing clinical studies and collaborations with device manufacturers are further advancing the market. The country’s well-established healthcare infrastructure ensures steady growth and adoption of Aquablation Therapy.
• India: India’s Aquablation Market is witnessing rapid growth due to increasing BPH cases and a rising preference for minimally invasive procedures. The cost-effectiveness of Aquablation compared to traditional surgeries is a key factor driving adoption. Local manufacturers are introducing affordable devices, supported by government initiatives to promote healthcare innovation. Growing awareness among urologists and patients about the benefits of Aquablation is expanding its reach. The increasing number of healthcare facilities equipped with advanced technology and the rising healthcare expenditure are expected to further propel market growth in India.
• Japan: Japan’s market for Aquablation Therapy is expanding with a focus on minimally invasive urological treatments. The country’s aging population has led to a higher incidence of BPH, increasing demand for effective solutions. Regulatory approvals and clinical evidence support the adoption of Aquablation. Leading medical centers are adopting the technology, and ongoing research aims to optimize treatment protocols. Japan’s emphasis on technological innovation and patient safety aligns with the adoption of Aquablation. The integration of advanced imaging and robotic systems is enhancing procedure precision, contributing to the market’s steady growth.

Features of the Global Aquablation Therapy Market

Market Size Estimates: Aquablation therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.

Segmentation Analysis: Aquablation therapy market size by various segments, such as by type, anesthesia type, site of care, application, and region in terms of value ($B).

Regional Analysis: Aquablation therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, anesthesia types, site of care, applications, and regions for the aquablation therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the aquablation therapy market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the aquablation therapy market by type (aquablation consoles, single-use handpieces, and imaging & planning software), anesthesia type (general anesthesia, spinal anesthesia, and others), site of care (inpatient OR, ambulatory surgery center, and others), application (benign prostatic hyperplasia, prostate tissue debulking, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order. Show more